| Research & Development
We aim to develop novel biopharmaceuticals by leveraging our exceptional scientific talent pool and developmental capabilities.
Biocon's discovery-led R&D focuses on the entire drug development pathway - from process development to non-clinical and clinical research. The depth and breadth of our technological and scientific expertise enables us to develop new and affordable therapeutics for the world's most debilitating diseases. R&D's ability to leverage frontier science, to develop solutions for small molecules to biosimilars to novel molecules, continues to advance Biocon's reputation as an emerging global biopharma focusing on delivering affordable innovation.
Our R&D team can boast of outstanding scientists from the best institutes around the world. The high quality scientific talent pool is engaged in continuous interaction with international thought leaders and participation in technical programs to enable knowledge creation, and the positioning of Biocon's R&D for challenging biopharmaceutical development.
To navigate the challenges of innovation we have adopted a well-defined strategic framework that will transform scientific discoveries into advances in human healthcare and generate incremental value for our shareholders.
The Innovation Matrix: A Strategic Framework
The ever-increasing cost of drug discovery and development, extended time to market, fierce competition and pressures to maintain margins are making tremendous demands on the biopharma industry. R&D gives Biocon the competitive edge, to grow its business exponentially.
Our R&D initiative is influenced by a four-dimensional innovation matrix ranging from known developments to unknown ideas. Creativity in the known realm builds on existing knowledge leading to two types of innovation (incremental and evolutionary). Creativity that pushes unknown boundaries and creates new knowledge is experimental and breakthrough in its impact to human existence.
By playing in all four quadrants of this innovation matrix, Biocon is able to create a balanced risk-reward profile. Our work on potentially the world's first oral insulin and first-in-class anti-CD6 antibody, Itolizumab, has the ability to change the treatment paradigm in diabetes and immunology, respectively. This breakthrough innovation carries huge risks but the rewards, both financial and societal, are tremendous.